{"entity":{"id":"nct04588922","kind":"trial","name":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","aka":[],"tldr":"A phase 1/2 trial of Venetoclax and Azacitidine in advanced solid tumours, run by Sellas Life Sciences Group, now recruiting.","summary":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML is a phase 1/2 interventional study registered as NCT04588922 by Sellas Life Sciences Group, with 160 participants planned, started 2021-05-10 and due to reach its primary completion in 2026-12-30. Interventions recorded: SLS009, venetoclax and azacitidine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04588922","url":"https://clinicaltrials.gov/study/NCT04588922"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["bcl2-inhibitors","cytotoxic-chemotherapy","epigenetic-drugs","kinase-inhibitors"],"targets":[],"drugs":["venetoclax","azacitidine"],"companies":["galena-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04588922","phase":"1/2","setting":"A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML","sponsor":"Sellas Life Sciences Group","started":"2021-05-10","startedType":"actual","enrolled":160,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04588922/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"galena-biopharma","kind":"company","name":"Galena Biopharma","route":"/companies/galena-biopharma/"}],"target":[{"id":"cdk9","kind":"target","name":"CDK9","route":"/targets/cdk9/"}]}}